Product Description
Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa2110956)
Mechanisms of Action: Mineralocorticoid Receptor Antagonist,MCRA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Chile | Croatia | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: Heart Failure | Heart Failure, Chronic | Myocardial Infarction | General Diabetes | Type 2 Diabetes | Kidney Diseases | Kidney Failure, Chronic
Known Adverse Events: Hypotension | Hyperkalemia | Hyponatremia
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 29
Highest Development Phases
Phase 3: Albuminuria|Diabetic Nephropathy|Glomerulonephritis|Heart Failure|Heart Failure, Acute|Hyperglycemia|Hypertension, Renal|IgA Nephropathy|Inflammation|Kidney Diseases|Kidney Failure, Chronic|Oxidative Stress|Prediabetes|Proteinuria|Type 1 Diabetes|Type 2 Diabetes
Phase 2: Kidney Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FIONA OLE | P3 |
Recruiting |
Proteinuria|Kidney Failure, Chronic |
2029-01-28 |
|
| 20186 | P3 |
Unknown Status |
Kidney Diseases|Proteinuria |
2028-09-10 |
|
| P01351 | P3 |
Unknown Status |
Kidney Diseases |
2028-08-31 |
|
| FIONA OLE | P3 |
Active, not recruiting |
Kidney Diseases|Proteinuria |
2028-03-04 |